CTLA4 and neoplasm: In expediting preclinical to clinical translation, Qiao et al. developed a QSP model of immuno-oncology to understand the variability in tumor kinetics in syngenetic mice treated with anti-CTLA4 antibody and proposed a combination regimen of anti-CTLA4 with therapeutics that expand CD8+ T cells for non-responding tumors [95].